Meta-Analysis
Copyright ©The Author(s) 2025.
World J Gastrointest Oncol. May 15, 2025; 17(5): 105148
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.105148
Table 1 Characteristics of studies included in the meta-analysis
Ref.
Country
Study type
Cut-off value
Method of measurement
Average age (years)
No. of patients (female/male)
Follow-up time (years)
Tseng et al[26], 2022ChinaCohortHBcrAg > 4.0 LogU/mLNA42.4 ± 10.1990 (351/639)Mean = 15.88
Hosaka et al[16], 2022JapanCohortiTACT-HBcrAg > 2.9 LogU/mLiTACT51.0 ± 9.9180Median = 11.0
Hsieh et al[18], 2023ChinaCase-controlHBcrAg ≥ 3.0 LogU/mLCLEIA55.0 (49.0-60.0)649 (245/404)1991-2014
Kaneko et al[19], 2021JapanCohortHBcrAg > 4.1 LogU/mLCLEIA54.0 (20.0-85.0)139Median = 5.3
Suzuki et al[23], 2021JapanCase-controliTACT-HBcrAg > 2.7 LogU/mLiTACT80.3 (44.0-70.0)17 (5/12)Not available
Liang et al[22], 2020ChinaCohortHBeAg-positive cohort: HBcrAg > 4.9 LogU/mLCLEIA53.5 ± 11.81400 (387/1013)Mean = 3.75
To et al[25], 2019ChinaCohortHBcrAg > 5.12 LogU/mLCLEIA40.0 (34.0-45.0)207 (89/118)Median = 13.1
Tseng et al[27], 2019ChinaCohortHBcrAg ≥ 4.0 LogU/mLCLEIA411211 (1050/161)Mean = 15.95
Suzuki et al[24], 2019JapanCross-sectionalHBcrAg ≥ 3.0 LogU/mLCLEIA54.8449 (296/153)Not available
Hosaka et al[17], 2019JapanCohortHBeAg-negative cohort: HBcrAg > 4.30 LogU/mLCLEIA44.0 (34.0-57.0)1268 (339/929)Median = 8.9
Ando et al[12], 2018JapanCohortHBcrAg > 3.4 LogU/mLCLEIA51.0 (20.0-79.0)133 (54/79)Median = 4.8
Chen et al[13], 2018ChinaCohortHBcrAg > 5.2 LogU/mLCLEIA52.5 (30.0-87.0)56Median = 5.0
Cheung et al[14], 2017ChinaCase-controlHBcrAg ≥ 3.89 LogU/mLCLEIAHCC: 61.3 (54.8-66.8)228 (39/189)Not available
Tada et al[28], 2016JapanCohortHBcrAg > 2.9 LogU/mLCLEIA49.0 (35.0-59.5)1031 (473/558)Median = 10
Honda et al[15], 2016JapanCohortHBcrAg > 3.0 LogU/mLCLEIA52.0 (30.0-79.0)109 (33/76)Mean = 6.5
Kumada et al[20], 2013JapanCohortHBcrAg > 2.9 LogU/mLCLEIA52.0 (21.0-77.0)234 (89/145)Median = 13.0
Kusakabe et al[21], 2011JapanCohortNot mentionedCLEIA55.2 ± 8.5479 (259/220)Mean = 12.7